Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $39.00 at JPMorgan Chase & Co.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) had its price target hoisted by investment analysts at JPMorgan Chase & Co. from $35.00 to $39.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s price objective indicates a potential upside of 171.19% from the company's previous close.

Other equities research analysts also recently issued reports about the stock. StockNews.com downgraded shares of Syndax Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, November 23rd. HC Wainwright restated a "buy" rating and issued a $51.00 price target on shares of Syndax Pharmaceuticals in a research note on Tuesday. The Goldman Sachs Group upped their price objective on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. Citigroup cut their target price on Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating on the stock in a research report on Tuesday. Finally, Scotiabank lowered their price target on Syndax Pharmaceuticals from $18.00 to $16.00 and set a "sector perform" rating for the company in a report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $36.00.

Syndax Pharmaceuticals Trading Down 7.1 %

NASDAQ:SNDX traded down $1.10 during midday trading on Tuesday, reaching $14.38. The company had a trading volume of 1,297,760 shares, compared to its average volume of 2,264,467. The stock's fifty day simple moving average is $14.23 and its 200-day simple moving average is $16.75. Syndax Pharmaceuticals has a 12-month low of $12.06 and a 12-month high of $25.16. The firm has a market capitalization of $1.23 billion, a price-to-earnings ratio of -3.98 and a beta of 0.90.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($1.10) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.79). The firm had revenue of $7.68 million during the quarter, compared to analyst estimates of $86.32 million. As a group, sell-side analysts expect that Syndax Pharmaceuticals will post -3.72 EPS for the current year.

Insider Activity

In other Syndax Pharmaceuticals news, insider Neil Gallagher sold 4,618 shares of the company's stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $71,579.00. Following the completion of the sale, the insider now directly owns 85,095 shares of the company's stock, valued at $1,318,972.50. This represents a 5.15 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Michael A. Metzger sold 13,288 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $205,964.00. Following the completion of the transaction, the chief executive officer now owns 300,121 shares in the company, valued at $4,651,875.50. This trade represents a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 21,683 shares of company stock valued at $336,087 in the last ninety days. 4.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Syndax Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of SNDX. Simplify Asset Management Inc. raised its position in Syndax Pharmaceuticals by 62.5% during the 3rd quarter. Simplify Asset Management Inc. now owns 122,185 shares of the company's stock worth $2,352,000 after buying an additional 46,992 shares during the last quarter. Franklin Resources Inc. lifted its position in Syndax Pharmaceuticals by 13.4% in the third quarter. Franklin Resources Inc. now owns 1,763,277 shares of the company's stock valued at $34,948,000 after purchasing an additional 208,043 shares during the period. State Street Corp boosted its holdings in Syndax Pharmaceuticals by 4.1% in the 3rd quarter. State Street Corp now owns 3,770,826 shares of the company's stock valued at $72,588,000 after purchasing an additional 148,491 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in Syndax Pharmaceuticals by 6.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 695,947 shares of the company's stock worth $13,397,000 after purchasing an additional 41,458 shares during the period. Finally, Barclays PLC raised its stake in shares of Syndax Pharmaceuticals by 143.4% during the 3rd quarter. Barclays PLC now owns 187,629 shares of the company's stock worth $3,612,000 after buying an additional 110,535 shares in the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.